Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Neurocrine Biosciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Neurocrine Biosciences's pe ratio was 25.6× on Nov 11, 2026, against 36.4× a year earlier. Over the last 5 years it ranged from 17.3× to 959.3×, with a median of 42.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 25.6× | −8.4 |
| 2025 | Dec 31, 2025 | 33.9× | −2.6 |
| 2024 | Dec 31, 2024 | 36.5× | −34.3 |
| 2023 | Dec 29, 2023 | 70.8× | −135.1 |
| 2022 | Dec 30, 2022 | 205.9× | +187.3 |
| 2021 | Dec 31, 2021 | 18.6× | −84.4 |
| 2020 | Dec 31, 2020 | 103.1× | −529.2 |
| 2019 | Dec 31, 2019 | 632.3× | +488.0 |
| 2013 | Apr 30, 2013 | 144.3× | +131.2 |
| 2012 | Oct 31, 2012 | 13.1× | +0.9 |
| 2011 | Dec 30, 2011 | 12.1× | – |
See a number that looks wrong?